AMR_Action_Fund
Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
Search
Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
2024 February pipeline
pipeline-february-2024
pipeline-june-2023
pipeline-october-2023
Pipeline - March 2023.pdf
January 2023 Updated Pipeline Infographic
Pipeline 2023
2023 Pipeline Infographic.pdf
October 2024 Pipeline
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Across Cancer Types
Across Cancer Types
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Therapeutics
Therapeutics
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Breakthrough Designation granted in US and China
SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
Transforming Science Day Europe
Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.
Cancer
Cancer
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced